9 Into C SRL
9 Into C reported total assets of 43,215 € at the end of the 2025 financial year (annual accounts filed with the NBB on 13 Jul 2026).
The score of 9 Into C shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
9 Into C's annual accounts
| 2025 | |
|---|---|
| Net result | 19,920 € |
| Equity | 19,920 € |
| Cash | 5,908 € |
| EBITDA | 29,139 € |
| Total assets | 43,215 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 13 Jul 2026
9 Into C's financial analysis
- Solvency46.1%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of 9 Into C
9 Into C's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1018.726.761
- VAT number
- BE1018726761
- Peppol
- Registered · 0208:1018726761 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 15 Jan 2025
- Registered office
- 9200 Dendermonde
- Latest accounts
- 2025 · filed on 13 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
9 Into C (SRL) has been based in Dendermonde since 2025, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 19,920 € and equity of 19,920 €; its revenue is not published. Its solvency stands at 46.1%, above the median of its sector (44.2%).
Companies similar to 9 Into C
Companies in the same business, of comparable size and area, outside its group.
- Hubert Services Management Retail sale of pharmaceutical products Estinnes · balance sheet 65,144 €
- Codema Pharma Retail sale of pharmaceutical products Brussels · balance sheet 375,959 €
- Dynaderm Retail sale of pharmaceutical products Wavre · balance sheet 47,613 €
- T.R.F. pharma Retail sale of pharmaceutical products Fléron · balance sheet 70,151 €
- Pharmacycle Retail sale of pharmaceutical products Brussels · balance sheet 41,191 €
- Kephas Pharma Retail sale of pharmaceutical products Pont-à-Celles · balance sheet 57,577 €
- Katrien Smets Retail sale of pharmaceutical products Heist-op-den-Berg · balance sheet 56,328 €
- Marc-Pharma Retail sale of pharmaceutical products Walcourt · balance sheet 36,076 €
Frequently asked questions about 9 Into C
What is the revenue of 9 Into C?
9 Into C files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of 9 Into C?
In Belgium, the VAT number is the company number prefixed with BE: BE1018726761 for 9 Into C, if the company is VAT-registered. Its company number (CBE) is 1018.726.761.
Where is the registered office of 9 Into C?
According to the CBE register, the registered office of 9 Into C is in 9200 Dendermonde.
What is the equity of 9 Into C?
At the close of the 2025 financial year, the equity of 9 Into C amounts to 19,920 €, a solvency of 46.1% of total assets.
Who manages 9 Into C?
The register lists 1 active mandates at 9 Into C. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of 9 Into C
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →